Dishman Carbogen Amcis Ltd Q3 FY26 Results

Summary

Dishman Carbogen Amcis Ltd, a fully integrated CDMO company, announces their Q3 & 9MFY26 results with a net revenue of Rs. 7,198 mn in Q3FY26 and Rs. 20,805 mn in 9MFY26. The CDMO segment's revenue is higher by 6.7% in Q3FY26 and marginally higher by 1.6% YoY in 9MFY26. The Marketable Molecules (MM) segment revenue decreased by 2.4% in Q3FY26 but increased by 21.5% in 9MFY26. The EBITDA margin is at 15.7% in Q3FY26 and 19.4% in 9MFY26.

Key Highlights

1. 1

   Net Revenue at Rs.7,198 mn in Q3FY26 up by 5.5% as compared to Rs. 6,823 mn in Q3FY25 mainly due to higher revenue from CDMO segment.

2. 2

   Net Revenue at Rs.20,805 mn in 9MFY26 up by 4.3% as compared to Rs. 19,952 mn in 9MFY25 mainly due to higher Cholesterol and Vitamin D analogues revenue contribution.

3. 3

   CDMO revenue for Q3FY26 is higher by 6.7% compared to Q3FY25 and marginally higher by 1.6% YoY in 9MFY26 primarily due to higher development revenue.

4. 4

   Marketable Molecules (MM) segment revenue for Q3FY26 decreased by 2.4% as compared to Q3FY25 primarily due to lower Quats revenue and MM revenue increased by 21.5% in 9MFY26 mainly due to increase in Cholesterol and Vitamin D analogues supplies.

5. 5

   EBIDTA Margin at 15.7% in Q3FY26 compared to 20.5% in Q3FY25 mainly due to Decrease in margins in CDMO segment from 22.1% to 16.9% QoQ and Decrease in margins in MM segment from 11.3% to 7.2% QoQ.

6. 6

   EBIDTA Margin at 19.4% in 9MFY26 compared to 15.9% in 9MFY25 mainly due to Increase in margins in CDMO segment from 17.2% to 19.7% YOY and Increase in margins in MM segment from 8.3% to 17.5% YoY.